Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of VSIG4 cytokine in preparation of medicament for treating hepatic failure

A liver failure, cytokine technology, applied in the fields of clinical medicine, molecular medicine and biomedicine, can solve the problem of lack of enhanced macrophage activation

Inactive Publication Date: 2019-11-15
杭州笙源生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

VSIG4 antagonizes the activation signal in macrophages by stimulating the PI3K / Akt-STAT3 cascade, enhancing the expression of pyruvate dehydrogenase kinase-2 (PDK2) and inhibiting pyruvate dehydrogenase (PDH) activity through phosphorylation, thus , VSIG4 deficiency enhanced macrophage activation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of VSIG4 cytokine in preparation of medicament for treating hepatic failure
  • Application of VSIG4 cytokine in preparation of medicament for treating hepatic failure
  • Application of VSIG4 cytokine in preparation of medicament for treating hepatic failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: Injection containing VSIG4 cytokines treats a large animal (young pig) model of liver failure

[0043] Animal model: 30 male Chinese young pigs (8-10 kg) were randomly divided into two groups, 15 in each group. Each young pig was injected with D-gal 1.5g / kg in the jugular vein to create a liver failure model.

[0044] Test group: Multiple intravenous injections of VSIG4 injection at fixed time points after D-gal injection, dose: 10ml / kg, twice a day.

[0045] Control group: inject the same amount of normal saline without VSIG4.

[0046] Neither the control group nor the experimental group received other drug treatment.

[0047] figure 1 It is a schematic diagram of the survival time curves of the young pigs of the experimental group and the control group, showing the survival rate of the young pigs of the experimental group and the control group. The results showed that the 3-day survival rate of young pigs in the treatment group containing VSIG4 cytok...

Embodiment 2

[0048] Embodiment 2: The lyophilized powder injection containing VSIG4 cytokine treats the small animal (rat) model of liver failure

[0049] Animal model: 100 male rats (200-250 g) were randomly divided into two groups, 50 in each group. Each rat was intraperitoneally injected with D-gal 1.5g / kg to make a liver failure model. Prepare VSIG4 lyophilized powder and water for injection to form a suspension.

[0050] Experimental group: 4 ml of VSIG4 freeze-dried powder suspension was injected intraperitoneally at a fixed time point after D-gal injection, twice a day.

[0051] Control group: inject the same amount of normal saline without VSIG4.

[0052] Both the control group and the experimental group received no other drug treatment.

[0053] figure 2 Schematic diagram of the survival time curves of rats in the experimental group and the control group, figure 2The survival rates of the rats in the experimental group and the control group were shown: the results showed th...

Embodiment 3

[0054] Embodiment 3: The suspension containing VSIG4 cytokine treats the rabbit model of liver failure

[0055] Animal model: 40 adult male rabbits (2000-2500 g) were randomly divided into two groups, 20 in each group. Each rabbit was intramuscularly injected with D-gal 1.5g / kg to make a liver failure model.

[0056] Test group: intramuscular injection of 20 ml of VSIG4 suspension at fixed time points after D-gal injection, twice a day.

[0057] Control group: inject the same amount of normal saline without VSIG4.

[0058] Both the control group and the experimental group received no other drug treatment.

[0059] image 3 It is a schematic diagram of the survival time curves of rabbits in the experimental group and the control group, image 3 The survival rate of rabbits in the experimental group and the control group is shown: the results show that the survival rate of the rabbits in the VSIG4 treatment group is 90% at 1 day and 80% at 7 days, while the survival rate at ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a VSIG4 cytokine in preparation of a medicament for treating hepatic failure. The dose form of the medicament is an injection or a lyophilized powder injection or a suspension, the application temperature of the VSIG4 cytokine-containing medicament is 15-30 DEG C, and the humidity is 45-75%. The VSIG4 is a member of an ABCA superfamily and is mainly used formediating transmembrane transport of lipids and regulating metabolic disorders such as hepatocyte steatosis during hepatic failure. In the application of the VSIG4 cytokine in preparation of the medicament for treating hepatic failure, the biochemical indexes of patients can be significantly improved, the bilirubin level is lowered, the transaminase is reduced, the blood coagulation function is improved, the albumin level is raised, hepatocyte death is inhibited, regeneration of hepatocytes and bile duct cells is promoted, fatal complications such as major upper gastrointestinal duct bleeding,severe hepatic encephalopathy and hepatorenal syndromes are prevented, the survival time is significantly prolonged, and the survival rate is increased.

Description

technical field [0001] The invention belongs to the fields of clinical medicine, molecular medicine and biomedicine, and is a new technology for treating liver failure with VSIG4 cytokine series drugs, specifically, an application of VSIG4 cytokine in the preparation of medicaments for treating liver failure. Background technique [0002] Liver failure is a kind of disease caused by extensive necrosis of the liver caused by various reasons. Except for orthotopic liver transplantation, there is currently no specific treatment. However, due to the severe shortage of donor livers, a large number of patients died while waiting for liver transplantation. Clarifying the pathogenesis of liver failure and early treatment targeting the mechanism can effectively block the progression of the disease and reduce the mortality rate, which is of great significance to the treatment of liver failure. [0003] V-set immunoglobulin domain 4 (VSIG4) is a membrane protein that belongs to the c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/19A61P1/16
CPCA61K38/19A61P1/16
Inventor 李君陈新李江石东燕
Owner 杭州笙源生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com